A review of forensic implications of opioid prescribing with examples from malpractice cases involving opioid-related overdose

Pain Medicine

Volumn 12, Issue SUPPL. 2, 2011, Pages

  Rich, Ben A ^a   Webster, Lynn R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Lifetree Clinical Research   (United States)

Author keywords

Chronic pain; Legal liability; Medical malpractice; Methadone; Mortality; Opioid related overdose

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DOXYLAMINE; FENTANYL; HYDROCODONE; METHADONE; OPIATE DERIVATIVE; OXYCODONE; PETHIDINE;

CHRONIC PAIN; COMORBIDITY; DRUG DOSE TITRATION; DRUG FATALITY; DRUG OVERDOSE; FORENSIC TOXICOLOGY; HUMAN; LAW SUIT; LAWYER; MALPRACTICE; MEDICAL ERROR; MEDICAL RECORD; MEDICATION ERROR; MENTAL DISEASE; MIDDLE AGED; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; RISK FACTOR; TREATMENT REFUSAL;

EID: 79958779440     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01129.x     Document Type: Review

References (21)

1. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief 2009;22:1-8.
2. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15(9):618-27.
3. Reason J. The nature of error. Human Error. New York, NY: Cambridge University Press; 1990:4.
4. Webster LR, Dove B, Murphy A. Select medical-legal reviews of unintentional overdose deaths. Presented at 2010 AAPM Annual Meeting, February 3-6, 2010, San Antonio, TX.
5. Prescribing information for Dolophine® hydrochloride CII (methadone hydrochloride tablets, USP) 5mg, 10mg. Roxane Laboratories, Inc. Columbus, Ohio, November 27, 2006. Available at: (accessed July 2010).
6. Agency Medical Directors' Group. Interagency guidelines on opioid dosing for chronic noncancer pain. 2010 Update. Olympia, WA, Washington State Agency Medical Directors' Group. Available at: (accessed August 2010).
7. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain 2010;26(suppl 10):S16-20.
8. Furrow BR, Greaney TL, Johnson SH, Jost TS, Schwartz RL. Health Law, 6th edition. St. Paul, MN: Thomson-West Publishing; 2008.
9. American Medical Association. Code of Medical Ethics. Chicago, IL: American Medical Association; 2006.
10. Medical Board of California. In the matter of the accusation against Eugene Whitney, MD. 2003. Available at: (accessed August 2010).
11. Vidmar N, Gross F, Rose M. Jury awards for medical malpractice and post-verdict adjustments of those awards. Depaul Law Rev 1999;48:265-99.
12. Bergman v. Chin, No. H205732-1 (Alameda Co. Ct. CA 2001).
13. Jacox AK, Carr DB, Payne R, etal. Management of cancer pain. Clinical Practice Guideline No. 9. Rockville, MD: Agency for Health Care Policy and Research, 1994 (AHCPR publication no. 94-0592).
14. Medical Board of California. Guidelines for prescribing controlled substances for pain. 1994 (revised 2007). Available at: (accessed November 2010).
15. Mello MM. Of swords and shields: The role of clinical practice guidelines in medical malpractice litigation. Univ Pa Law Rev 2001;149:645-710.
16. Controlled Substances Act. 21 USC § 353(b).
17. Drug Enforcement Administration Final Policy Statement. Dispensing controlled substances for the treatment of pain. 2006.Available at: (accessed August 2010).
18. United States v. Hurwitz, 459 F. 3d 463 (4th Cir. 2006).
19. State v. Naramore, 965 P. 2d 211 (Kan. 1998).
20. Groopman J. How Doctors Think. Boston, MA: Houghton Mifflin Company; 2007.
21. Goldenbaum DM, Christopher M, Gallagher RM, etal. Physicians charged with opioid analgesic-prescribing offenses. Pain Med 2008;9(6):737-47.